Back to top
more

Equillium (EQ)

(Real Time Quote from BATS)

$1.72 USD

1.72
43,122

-0.09 (-4.97%)

Updated Apr 26, 2024 02:37 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sweta Killa headshot

5 Stocks That More Than Doubled in Q1 With More Gains Ahead

Equillium (EQ), Laird Superfood (LSF), QuantaSing (QSG), Phunware (PHUN) and Arq (ARQ) more than double in the first quarter and are expected to continue their strong performances.

Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates

Equillium (EQ) delivered earnings and revenue surprises of 58.82% and 4.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates

HOOKIPA Pharma (HOOK) delivered earnings and revenue surprises of 45% and 105.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates

Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of -5.88% and 99.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark

Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark are included in this Analyst Blog.

Sweta Killa headshot

5 Stocks That More Than Doubled in February

Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -12.60% and 19.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

5 Top-Ranked Stocks That Have More Than Doubled Year to Date

Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.

Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates

Equillium, Inc. (EQ) delivered earnings and revenue surprises of 47.37% and 6.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

Equillium, Inc. (EQ) delivered earnings and revenue surprises of 45% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)

Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19

Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.

Is Equillium (EQ) Stock Outpacing Its Medical Peers This Year?

Is (EQ) Outperforming Other Medical Stocks This Year?

Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Equillium Gains From Positive Results on Coronavirus Drug

Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.

Will Equillium Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Equillium.

Equillium Sees Hammer Chart Pattern: Time to Buy?

Equillium has been struggling lately, but the selling pressure may be coming to an end soon.

Can The Uptrend Continue for Equillium?

As of late, it has definitely been a great time to be an investor Equillium

Equillium Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Equillium.